Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea

Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea

A Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea

Inclusion Criteria:

• Diagnosis of rosacea according to the criteria established by the ROSacea COnsensus (ROSCO) 2019 guidelines.
• Presence of obvious facial erythema accompanied by significant burning and tingling sensations, with subjective symptoms (e.g., burning and tingling) being more severe than the observable clinical signs.
• Refractory facial erythema despite conventional treatment, including antibiotics (metronidazole, doxycycline, and minocycline), oral isotretinoin, and oral beta-blockers.

Exclusion Criteria:

• Facial inflammatory dermatoses such as acne, contact dermatitis, seborrheic dermatitis, or other facial skin diseases.
• Pregnancy or lactation.
• Hepatic or renal insufficiency.
• Ongoing treatment with long-term topical glucocorticoids or retinoids.